Chemical Name: (6S)-4-(4-Chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-6-acetic acid 1,1-dimethylethyl ester
Biological ActivityPotent, high affinity, selective BET bromodomain inhibitor (IC50 values are 17.7, 32.6, 76.9 and 12942 nM for BRD2 (N-terminal (N)), BRD4 (C-terminal (C)), BRD4 (N) and CREBBP respectively; Kd values are 49, 59.5, 82, 90.1, 128 and 190 nM for BRD4 (N), BRD3 (N), BRD3 (C), BRD4 (C), BRD2 (N) and BRDT (N) respectively). Induces squamous differentiation in NUT midline carcinoma (NMC) cell lines; inhibits tumor growth in NMC xenograft models in vivo. Exhibits reversible contraceptive effects in germ cells from male mice.
Inactive Analog also available.
External Portal InformationChemicalprobes.org is a portal that offers independent guidance on the selection and/or application of small molecules for research. The use of (+)-JQ1 is reviewed on the chemical probes website.
The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Selective inhibition of BET bromodomains.
Filippakopoulos et al.
Small-molecule inhibition of BRD4 as a new potent approach to eliminate leukemic stem- and progenitor cells in acute myeloid leukemia AML.
Herrmann et al.
Oncotarget. [Epub ahead of print], 2012;3:1588
Small-molecule inhibition of BRDT for male contraception.
Matzuk et al.
Citations for (+)-JQ1
The citations listed below are publications that use Tocris products. Selected citations for (+)-JQ1 include:
12 Citations: Showing 1 - 10
BET protein targeting suppresses the PD-1/PD-L1 pathway in triple-negative breast cancer and elicits anti-tumor immune response.
Authors: Andrieu Et al.
Cancer Lett 2019;465:45
Activity of BET-proteolysis targeting chimeric (PROTAC) compounds in triple negative breast cancer.
Authors: Noblejas-Lopez Et al.
J Exp Clin Cancer Res 2019;38:383
Super-Enhancer-Associated LncRNA UCA1 Interacts Directly with AMOT to Activate YAP Target Genes in Epithelial Ovarian Cancer.
Authors: Lin Et al.
Bromodomain protein BRD4 inhibitor JQ1 regulates potential prognostic molecules in advanced renal cell carcinoma.
PTBP1-Mediated Alternative Splicing Regulates the Inflammatory Secretome and the Pro-tumorigenic Effects of Senescent Cells.
Authors: Georgilis Et al.
Cancer Cell 2018;34:85
IRE1α RNase-dependent lipid homeostasis promotes survival in Myc-transformed cancers.
Authors: Xie Et al.
J Clin Invest 2018;128:1300
VEGF amplifies transcription through ETS1 acetylation to enable angiogenesis.
Nat Commun 2017;8(1):383
AMPK-ULK1-Mediated Autophagy Confers Resistance to BET Inhibitor JQ1 in Acute Myeloid Leukemia Stem Cells.
Authors: Jang Et al.
Clin Cancer Res 2017;23:2781
MYCL is a target of a BET bromodomain inhibitor, JQ1, on growth suppression efficacy in small cell lung cancer cells.
Authors: Kato Et al.
Reprogramming by De-bookmarking the Somatic Transcriptional Program through Targeting of BET Bromodomains.
Authors: Shao Et al.
Cell Rep 2016;16:3138
Epigenetic Readers of Lysine Acetylation Regulate Cocaine-Induced Plasticity.
Authors: Sartor Et al.
J Neurosci 2015;35:15062
BET bromodomains regulate transforming growth factor-β-induced proliferation and cytokine release in asthmatic airway smooth muscle.
Authors: Perry Et al.
Nat Commun 2015;290:9111
No product specific FAQs exist for this product, however you mayView all Small Molecule FAQs
Reviews for (+)-JQ1
There are currently no reviews for this product. Be the first to review (+)-JQ1 and earn rewards!
Have you used (+)-JQ1?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image